Immunome Reports Full Year 2024 Financial Results and Provides Business Update
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025.First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy.Projected cash runway extends into 2027 BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update.“Immunome’s efficient execution in 2024 laid the foundation for a productive 2025,” said Clay B. Siegall, Ph.D., President and Chie
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $23.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates [Yahoo! Finance]Yahoo! Finance
- Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.MarketBeat
- Immunome, Inc. (NASDAQ: IMNM) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.MarketBeat
- Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Guggenheim from $35.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
IMNM
Earnings
- 11/13/24 - Miss
IMNM
Sec Filings
- 3/28/25 - Form 4
- 3/26/25 - Form 4
- 3/26/25 - Form 4
- IMNM's page on the SEC website